Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia

Expert Opinion on Emerging Drugs
Simon KavanaghJeffrey H Lipton

Abstract

BCR-ABL-directed tyrosine kinase inhibitors (TKIs) have revolutionised therapy for chronic myeloid leukemia. However, despite the availability and efficacy of this class of agents, lifelong treatment is still required in a significant proportion of patients Areas covered: We give an overview of the currently available BCR-ABL-directed TKIs and other conventional therapies for CML. We proceed to review the current market and some of the scientific rationale for new drug development before outlining a number of novel therapies, considered broadly as immunotherapies and targeted agents. Published English-language literature was reviewed regarding currently available TKIs; clinical trials repositories were reviewed to identify novel agents recently investigated or under active study. Expert opinion: We recommend discussion with patients and enrolment on an appropriate clinical trial where feasible. In situations where no trials are available, or if patients decline enrolment, we recommend use of an appropriate BCR-ABL directed TKI, selected on the basis of an evaluation of patient risk factors and side effect profile. Allogeneic stem cell transplant continues to have a role though this is generally limited to cases with advanced ph...Continue Reading

References

Apr 15, 1994·Annals of Internal Medicine·R P GaleM M Bortin
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 8, 2001·Blood·F BonifaziUNKNOWN Swedish CML Study Group
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Jul 24, 2004·Hematology/oncology Clinics of North America·Francis J GilesSusan M O'Brien
May 3, 2005·Nature Reviews. Immunology·Leonidas C Platanias
May 11, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre J IssaHagop M Kantarjian
Dec 13, 2005·Pharmacy World & Science : PWS·Stefan SleijferGerrit Stoter
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Simona SoveriniUNKNOWN GIMEMA Working Party on Chronic Myeloid Leukemia
Mar 7, 2008·Blood·Seonaid M PyeJane F Apperley
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dragana Milojkovic, Jane Apperley
Jan 6, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·B Douglas SmithHyam I Levitsky
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Dec 24, 2010·The New England Journal of Medicine·Claude PreudhommeUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
Oct 19, 2011·Future Medicinal Chemistry·Antonio T BainesChanning J Der
Nov 1, 2011·Blood·Alice FabariusUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Dec 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniela Cilloni, Giuseppe Saglio
Jun 14, 2012·Blood·Simona LuattiUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz

❮ Previous
Next ❯

Citations

Jun 22, 2018·Journal of Hematology & Oncology·Federico RossariEnrico Orciuolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Current Hematologic Malignancy Reports
Zachariah DeFilipp, H J Khoury
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Xiang-Long LiTing Liu
Expert Opinion on Emerging Drugs
Carmen FavaGiovanna Rege-Cambrin
© 2022 Meta ULC. All rights reserved